Get the Stockscreener App
89.52
1.81%
-1.65
After Hours:
89.52
Guardant Health Inc stock is traded at $89.52, with a volume of 1.38M.
It is down -1.81% in the last 24 hours and down -4.59% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$91.17
Open:
$91.87
24h Volume:
1.38M
Relative Volume:
0.68
Market Cap:
$11.87B
Revenue:
$982.02M
Net Income/Loss:
$-416.28M
P/E Ratio:
-27.01
EPS:
-3.3148
Net Cash Flow:
$-233.07M
1W Performance:
+7.74%
1M Performance:
-4.59%
6M Performance:
-5.82%
1Y Performance:
+103.22%
1-Day Range:
$87.57
$93.00
1-Week Range:
$79.01
$93.00
52-Week Range:
$36.36
$120.74
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
89.52 | 12.09B | 982.02M | -416.28M | -233.07M | -3.3148 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Reiterated | Canaccord Genuity | Buy |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health India Launch: ₹1.4 Lakh Cancer Test par Hote Bawal? Zydus ne ki partnership! - Whalesbook
The Bull Case For Guardant Health (GH) Could Change Following New ESR1 Liquid Biopsy CDx Approval – Learn Why - Yahoo Finance
Why is Guardant Health stock falling on Tuesday? - MSN
Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy - Benzinga
Guardant Health (GH) Receives FDA Approval for Liquid Biopsy Tes - GuruFocus
FDA approves Guardant360 CDx as companion diagnostic for VEPPANU - Investing.com
Does Guardant Health (GH) Have Long-Runway for Growth? - Insider Monkey
Guardant blood test wins FDA approval to guide VEPPANU use in breast cancer - Stock Titan
MSN Money - MSN
Pictet Asset Management Holding SA Sells 89,386 Shares of Guardant Health, Inc. $GH - MarketBeat
Short Interest in Guardant Health, Inc. (NASDAQ:GH) Decreases By 15.0% - MarketBeat
Director at Guardant Health (GH) exercises 154 RSUs and holds 19,362 shares - Stock Titan
Guardant Health, Inc. $GH Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Comerica Bank Grows Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
GH Stock Price, Quote & Chart | GUARDANT HEALTH INC (NASDAQ:GH) - ChartMill
Guardant Health (GH) Experiences 4% Decline in Midday Trading - GuruFocus
Lagoda Investment Management, L.P.'s Guardant Health Inc(GH) Holding History - GuruFocus
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform - BioSpace
INVESCO V.I. Small Cap Equity Fund's Guardant Health Inc(GH) Holding History - GuruFocus
Guardant Health partners with Nuvalent on diagnostic tests By Investing.com - Investing.com South Africa
Vanguard holds 6.59M shares of Guardant Health (NYSE: GH) — 5.02% stake - Stock Titan
Delta Investment Management LLC Buys Shares of 22,236 Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. $GH Position Trimmed by Jennison Associates LLC - MarketBeat
Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Analysts Conflicted on These Healthcare Names: CareDx (CDNA), Biogen (BIIB) and Guardant Health (GH) - The Globe and Mail
Guggenheim Keeps Their Buy Rating on Guardant Health (GH) - The Globe and Mail
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market - openPR.com
Guardant Health partners with Nuvalent on diagnostic tests - Investing.com
Guardant Health Inc. announces a multi-year strategic partnership with biopharmaceutical company Nuvalent - Bitget
Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Guardant Health (GH) to Release Earnings on Thursday - MarketBeat
EBITDA per share of Guardant Health, Inc. – DUS:5GH - TradingView
Guardant Health lines up three investor conference webcasts - Stock Titan
Guardant Health to Participate in Upcoming Investor Conferences - marketscreener.com
Guggenheim Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $135 - Moomoo
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), Pfizer (PFE) and Guardant Health (GH) - The Globe and Mail
Guardant Health (GH) Faces Minimal Impact from AstraZeneca Advis - GuruFocus
Guardant Health slides as FDA briefing raises questions tied to AstraZeneca camizestrant review - Quiver Quantitative
[ARS] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health (NASDAQ: GH) grows to $982M revenue and details 2026 shareholder meeting - Stock Titan
Guardant Health (GH) Shares Decline Amid FDA Concerns Over Camiz - GuruFocus
Why Is Guardant Health Stock Falling On Tuesday? - Benzinga
Canaccord reiterates Guardant Health stock rating ahead of FDA meeting By Investing.com - Investing.com South Africa
Canaccord reiterates Guardant Health stock rating ahead of FDA meeting - Investing.com
PD Small-Cap Growth Index Portfolio's Guardant Health Inc(GH) Holding History - GuruFocus
Guardant Health Announces Resignation of Chief Medical Officer - TipRanks
Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care - MSN
Guardant Health, Inc. Announces Resignation of Craig Eagle, M.D. as Chief Medical Officer, Effective May 8, 2026 - marketscreener.com
CMO Craig Eagle to leave Guardant Health (NASDAQ: GH) May 8 - Stock Titan
Teachers Retirement System of The State of Kentucky Sells 13,646 Shares of Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (GH) Stock Analysis: Unpacking A 44% Potential Upside For Investors - DirectorsTalk Interviews
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):